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Revascularization in
Patients Undergoing
Primary Percutaneous
Coronary Intervention
for STEMIIs it Really What We Should Be Doing?We read with interest the work by Gershlick et al. (1),
which reported that in patients with ST-segment
elevation myocardial infarction and multivessel
coronary artery disease undergoing infarct-artery
percutaneous coronary intervention (PCI), complete
revascularization in noninfarct coronary arteries
with major stenoses signiﬁcantly reduces the risk of
adverse cardiovascular events, as compared with
PCI limited to the infarct-related artery. We feel the
management of the latter group (infarct-related artery
PCI only) was not per the current European Society of
Cardiology guideline (2), which recommends using
either a conservative (symptom-/noninvasive
ischemia–guided) strategy or a staged revasculariza-
tion approach (preferably fractional ﬂow reserve–
guided) performed several days or weeks after primary
percutaneous coronary intervention (PPCI). The meta-
analysis by Vlaar et al. (3) has clearly shown that when
signiﬁcant nonculprit vessel lesions are suitable for
PCI, they should only be treated during staged
procedures.Of the patients presenting with ST-segment
elevation myocardial infarction, 40% to 65% have
multivessel disease. The severity of nonculprit
stenosis can be overestimated during infarct angio-
graphy, potentially leading to inappropriate decision
making in a non-negligible number of patients (4).
In CvLPRIT (Complete Versus Lesion-Only Primary
PCI Trial), the bystander lesion was considered sig-
niﬁcant if stenosis was >70% in 1 angiographic view
or >50% in 2 views. If the latter cut-off was to be
applied to deﬁne multivessel disease, this could
lead to a large number of procedures, if complete
revascularization strategy was adopted, with an
inevitable major impact on the PPCI service provi-
sion. Adenosine stress cardiac magnetic resonance 1
to 5 days after ST-segment elevation myocardial
infarction is safe and can allow accurate detection of
signiﬁcant nonculprit territory stenosis. A recent
study by our group (5) demonstrated that <40% of
patients undergoing PPCI with moderate to severe
bystander nonculprit coronary artery disease need
further revascularization, when stress cardiac mag-
netic resonance was used as a gatekeeper to complete
revascularization.
We do not believe that the control group in
CvLPRIT reﬂects current practice. The question of
how and when best to deal with bystander lesions
detected during PPCI remains unanswered. We feel
that caution should be used in directly translating the
results of this trial in clinical practice, and in
considering immediate complete revascularization
merely on the presence of multivessel disease. In-
hospital invasive or noninvasive ischemia assess-
ment should perhaps play a greater role in the
decision making process, especially in the bystander
disease of moderate stenosis severity. A large ran-
domized study that is adequately powered for mor-
tality is immediately warranted to answer this.Amardeep Ghosh Dastidar, MBBS(Hons)
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REPLY: Complete Revascularization inPatients Undergoing Primary Percutaneous
Coronary Intervention for STEMI
Is It Really What We Should Be Doing?We read with interest the letter from Dr. Dastidar and
colleagues in which they express their views and
compare our report of the randomized CvLPRIT
(Complete Versus Lesion-Only Primary PCI Trial) (1)
with their in-house clinical experience.
They suggest that the trial was not run according to
current European Society of Cardiology guidelines. In
fact, it remains unclear how best to manage multi-
vessel disease ST-segment elevation myocardial
infarction patients and in the last iteration of the Eu-
ropean Society of Cardiology ST-segment elevation
myocardial infarction guidelines this was listed as a
“Gap in the Knowledge.” Furthermore, the strategy
suggested by Dr. Dastidar and colleagues (of routine
noninvasive testing) is not within the guidelines,
although the control group in CvLPRIT could undergo
intervention on the non-infarct-related artery if there
were reliable symptoms and evidence of ischemia on
subsequent noninvasive testing. Importantly, the
meta-analysis they quote (Vlaar et al. [2]) was pub-
lished before the 2 most signiﬁcant randomized
controlled trials (PRAMI [Preventive Angioplasty
in AcuteMyocardial Infarction] and CvLPRIT), so itwas
unlikely to have found overall beneﬁt for intervention.
In CvLPRIT, as a safety measure, all patients had a
“nested” myocardial perfusion scan at 6 weeks, with
the intention that information on any patient with
>20% left ventricular ischemic burden be sent to
the responsible physician (A. Keilon, unpublished
data, June 2015). In essence, no patients needed to beso reported, which brings the debate to the issue of the
value of ischemia testing in such patients.Whether it is
the stability of the lesion rather than the presence of
signiﬁcant physiological ﬂow reduction that leads
to non-infarct-related artery lesion-driven adverse
outcomes remains undetermined. Indeed, there is no
evidence in the primary percutaneous coronary inter-
vention era to support the use of ischemia testing to
guide management. Furthermore, both CvLPRIT and
PRAMI have shown a beneﬁt of in-hospital complete
revascularization with early separation of the survival
curves, which suggests that beneﬁts may accrue from
mechanisms other than ischemia reduction.
CvLPRIT was consistent with PRAMI in demon-
strating signiﬁcant beneﬁt from total revasculariza-
tion. However, as has been stated in our paper (1), and
during presentations, we never purported to have the
whole answer.What these 2 trials have done is raise the
issue of how best to manage such patients. They were
insufﬁciently powered for death and myocardial
infarction, and larger trials are needed and planned,
including one by the CvLPRIT and PRAMI investi-
gators, which will be powered for death and myocar-
dial infarction and will assess the value of fractional
ﬂow reserve in the non-infarct-related artery.
In the meantime, physicians must make their own
judgment and, if faced with an angiographically
signiﬁcant lesion in the proximal portion of the right
coronary artery in a patient presenting with a left
anterior descending ST-segment elevation myocar-
dial infarction, decide, based on the current ran-
domized data (see meta-analysis by El-Hayek et al.
[3]) whether it is in the patient’s best interest to
choose to leave this non-infarct-related artery lesion
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